Latest Administration News

Bod Science Limited reported a $576,000 net operating cash outflow for the September quarter, sustained by funding from Biortica Agrimed Limited under a Deed of Company Arrangement as it pursues a backdoor listing.

Highfield Resources has locked in A$10 million through convertible notes from existing investors to tackle a key permit issue and push forward its flagship Muga Potash Project in Spain.

Clarity Pharmaceuticals’ Co-PSMA Phase II trial shows its Cu-SAR-bisPSMA diagnostic agent detects more prostate cancer lesions than current standard imaging, promising earlier and more accurate recurrence detection.

Pacific Edge reports a 9% decline in Cxbladder test volumes amid Medicare coverage loss but gains momentum with new clinical validation and a CMS pricing boost.

Clime Investment Management has completed a $2.3 million placement and announced a bonus option issue, positioning itself for growth as the Australian wealth management sector consolidates.

Immutep Limited has confirmed 30 mg as the optimal biological dose for its immunotherapy efti, following FDA approval of Project Optimus requirements. This milestone paves the way for the US launch of its pivotal Phase III lung cancer trial.

Artrya Limited has successfully navigated a key FDA Q-Submission meeting, receiving clear guidance on the regulatory pathway for its Salix Coronary Flow module, with a 510(k) submission planned by year-end.

Prescient Therapeutics has bolstered its cash reserves to $12.3 million following a $9.8 million capital raise, while progressing its PTX-100 cancer therapy through global Phase 2 trials with encouraging early lymphoma results.

Discovery Alaska Limited has detailed its exploration expenditures and strategic pivot from Alaskan projects to new US acquisitions, affirming its financial health and operational sufficiency to maintain its ASX listing.

Fiducian Group Limited has reported a robust 23% increase in net profit after tax for the year ended June 2025, driven by strong inflows and resilient performance across its financial planning, platform administration, and investment management segments despite challenging market conditions.

Wellard Limited has formally requested to delist from the ASX following the sale of its final revenue-generating vessel, aiming to reduce costs and return excess cash to shareholders. The move awaits shareholder approval at the upcoming AGM.

EVE Health Group has raised $1.1 million to accelerate the commercial rollout of its innovative pharmaceutical products Dyspro and Libbo, signaling strong investor confidence in its growth strategy.